Cancer research has come a long way, although dreams of curing cancer as a whole persist. Researchers have found ways to get the disease under control, as well as how to help people become cancer free. The treatment options available for cancer patients are radiation therapy, immunotherapy, chemotherapy, as well as surgeries to cut out or treat targeted areas. However, a groundbreaking study has helped researchers develop a new cancer treatment, that has increased the rate of survival by 40%.Researchers from Peking University Cancer Hospital & Institute in China, whose findings were published in The Lancet medical journal, stated that this method "could represent a paradigm shift" in care. These exciting results were shared at the American Society of Clinical Oncology's (ASCO) annual conference in Chicago. This study is the first-ever randomized controlled trial to investigate CAR-T therapy for solid tumors. Randomized controlled trials are considered the gold standard for proving whether a treatment is effective. Major Leap for Solid TumorsNow, a significant study presented at the world's largest cancer conference has revealed that CAR-T therapy could also fight solid tumors, which make up about 90% of all adult human cancers. The research, involving over 100 patients with advanced stomach or gastro-oesophageal junction (GEJ) cancer, showed that those treated with CAR-T therapy lived 40% longer on average than patients who received standard care.CAR-T therapy is a form of immunotherapy where the treatment cells are made by the patient’s own T-cells, which are white blood cells that protect our bodies from infections. These cells are used to fight cancer, according to the National Cancer Institute. Experts call it the “living drug”, as the T-cells are collected from the patients blood, and modified to produce a special protein called chimeric antigen receptors, or CARs. These cells then latch onto the antigens present in the cancer cells. They also enhance the ability of T-cells to kill cancer.Specifically, patients who got CAR-T cell therapy survived for an average of 7.9 months, compared to 5.5 months with standard care. They also had 3.3 months without their cancer getting worse, compared to 1.8 months for those on standard care. What Does This Mean For Future Cancer Treatments? Experts are hailing this as a "groundbreaking milestone" for using CAR-T therapies to treat solid tumors. Some found the results "exciting," calling it a crucial moment that should motivate the cancer research community to keep pushing forward. A director of research and partnerships at a prominent cancer research organization found it "encouraging" to see early signs that CAR-T cell therapy could help patients with solid tumors. They noted that while more extensive trials are needed before it can be widely used, it could mark an important step ahead for patients who have had limited treatment options so far. Researchers highlighted that the treatment only extended survival by about two months. They also emphasized the importance of finding ways to lower the cost of CAR-T therapy to make it widely accessible. Despite this, they expressed encouragement that this represents another potential treatment option for gastric cancer patients, whose prognosis is generally very poor, hoping it could offer "meaningful longevity."